Acute intermittent porphyria




Hematological system

Heme synthesis disorders
Coagulation disorders
Platelet disorders
Mixed platelet and coagulation disorders
Thrombosis syndromes (hypercoagulability)
Leukemoid reaction
Dysplastic and proliferative disorders
Plasma cell dyscrasias
Hematological system pathology review

Acute intermittent porphyria


0 / 8 complete


1 / 2 complete
High Yield Notes
4 pages

Acute intermittent porphyria

8 flashcards

are the treatments for acute intermittent porphyria as they inhibit delta-aminolevulinic acid synthase, the first enzyme involved in heme synthesis.


USMLE® Step 1 style questions USMLE

2 questions

A 48-year-old man comes to the emergency department because of recurrent abdominal pain and vomiting, which he has had for over 7 years. His wife says that lately, all he does is complain about the pain, and that he is very anxious and paranoid. She also says that he abuses alcohol, and that he finished four glasses of vodka right before coming to the emergency department. She worries because he’s becoming more and more like his father who had similar symptoms and habits. Physical examination shows multiple scars in the abdomen from exploratory laparotomies that he has had in the past to investigate his long-standing abdominal pain. His temperature is 36.5°C (97.7°F), pulse is 118/min, respirations are 17/min, and blood pressure is 138/70 mm Hg. Laboratory studies show no abnormalities. Assuming that there is an underlying metabolic cause for this condition, which of the following enzymes is most likely affected? 

External References

Content Reviewers:

Yifan Xiao, MD

Acute intermittent porphyria is a rare autosomal dominant disorder that belongs to a family of disorders called porphyria.

These disorders all affect the production of heme which is a major component of red blood cells.

Now, heme synthesis is also called porphyrin synthesis and when halted, it result in the buildup of one of its precursors molecules.

In order to better understand acute intermittent porphyria, we need to first take a look at hemoglobin, the main protein within red blood cells that’s responsible for carrying oxygen.

Now hemoglobin is made up of hemes and globins.

There are 4 globin subunits, typically two alpha and two beta, and each one has its own heme group.

This heme is a large molecule that’s made up of four pyrrole subunits that forms a ring, and this structure is called a porphyrin.

In the middle, there an ionically bond iron 2+ and the iron is what binds to and carries the oxygen molecule.

So each hemoglobin can carry four oxygen molecules when it’s fully saturated.

The process of heme synthesis occurs both within the mitochondria and the cytosol of a cell and requires multiple enzymes to catalyze the numerous steps.

It begins in the mitochondria where succinyl CoA binds to glycine via delta-ALA synthase to produce delta-aminolevulinic acid, or ALA.

Then, in the cytosol, delta-aminolevulinic acid is converted to porphobilinogen, or PBG, via delta-ALA dehydratase.

From there, four molecules of porphobilinogen condense together to form hydroxymethylbilane with the help of porphobilinogen deaminase.

Note that porphobilinogen deaminase is sometimes called uroporphyrinogen I synthase or hydroxymethylbilane synthase, or HMBS for short.

Afterwards, hydroxymethylbilane is converted to uroporphyrinogen III and catalyzed to coproporphyrinogen III via uroporphyrinogen III cosynthase and uroporphyrinogen decarboxylase, respectively.

Next, coproporphyrinogen III is brought back into the mitochondria and converted into protoporphyrinogen IX by coproporphyrinogen oxidase.

Lastly, an iron molecule is added to protoporphyrin IX via the enzyme ferrochelatase, and viola! We got ourselves a completed heme!

So, the porphyria disorders occur when one of the enzymes in the heme synthesis pathway is deficient, which causes a decrease in heme synthesis and a buildup of metabolites formed in the earlier steps of the pathway.

Now individuals with acute intermittent porphyria have a mutation of the HMBS gene which codes for the enzyme porphobilinogen deaminase.

Without this enzyme, porphobilinogen cannot be converted to hydroxymethylbilane and the heme synthesis pathway can’t continue.

Furthermore, it causes the buildup of the earlier metabolites like porphobilinogen and aminolevulinic acid, which can be toxic to the body.

The majority of individuals with the HMBS gene mutation and a deficiency of porphobilinogen deaminase are asymptomatic.